CAR-T Trials Safety Concerns Halt by Novartis and BMS
Overview of CAR-T Trials Halted
CAR-T therapy, a groundbreaking approach in treating autoimmune diseases, has encountered challenges as Novartis and BMS have paused their trials. These decisions are influenced by emerging safety concerns that arise during the therapeutic process.
Impact on the Industry
This halt not only affects immediate clinical trials but also raises questions regarding the future of CAR-T therapies in general. As the industry grapples with these developments, there's a noteworthy dealmaking roundup involving companies like Alteogen and their licensing arrangements with Novartis.
Future Partnerships
- NewBiologix is entering a partnership in gene therapy aimed at enhancing treatment options.
- This collaborative effort underscores a shift towards more innovative solutions.
For more details on these significant events impacting the pharmaceutical industry, please visit the original source.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.